<- Go Home

PharmaResearch Co., Ltd.

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults through the physical restoration; Rejuran HB plus which is used for temporary improvement of adult's crow's feet wrinkles; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; and Rejuvenex cream, which treats the wound through rapid tissue regeneration. It also provides REJURAN, a medical device for face (especially eye, perioral area), neck, Décolleté, hands, etc; CLEVIEL prime plus and contour plus with lidocaine medical devices; D+CELL 350 TRA I; and REJURAN moisturizer for daily skin protection, as well as REJUVENEX SCULPT V; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. In addition, the company offers D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; REJURAN FORTE; and CONJURAN medical devices. Further, it offers functional foods; and engages in the development of software and consulting businesses. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Gangneung-si, South Korea.

Market Cap

KRW 2.4T

Volume

153.3K

Cash and Equivalents

KRW 95.1B

EBITDA

KRW 117.8B

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

KRW 211.0B

Profit Margin

71.14%

52 Week High

KRW 238.0K

52 Week Low

KRW 86.8K

Dividend

N/A

Price / Book Value

4.99

Price / Earnings

28.15

Price / Tangible Book Value

5.33

Enterprise Value

KRW 2.3T

Enterprise Value / EBITDA

18.29

Operating Income

KRW 105.3B

Return on Equity

19.64%

Return on Assets

11.91

Cash and Short Term Investments

KRW 206.1B

Debt

KRW 35.1B

Equity

KRW 509.1B

Revenue

KRW 296.6B

Unlevered FCF

KRW 45.1B

Sector

Biotechnology

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches